Estonia

Pharmacovigilance activities in Estonia are regulated by the State Agency of Medicines (Ravimiamet) under EU pharmacovigilance legislation and EU GVP. The MAH must operate an EU-compliant pharmacovigilance system, appoint an EU/EEA QPPV, maintain an EU/EEA PSMF, report ICSRs through EudraVigilance and comply with applicable PSUR, signal-management and RMP obligations. Current official guidance does not establish a routinely mandatory separate Estonian QPPV; authority communication details must nevertheless be maintained, and the system may be inspected. As an EU/EEA jurisdiction, the EU pharmacovigilance framework applies to the EU QPPV and Union PSMF, EudraVigilance ICSR reporting, applicable PSURs, RMPs, signal management, quality-system audits and competent-authority inspections. MAHs should also check current national submission channels, contact arrangements and language requirements. BAUPHARMA supporting resources (operational context only, not national regulatory evidence): Difference in QPPV Nomination Between EU and KSA; PSMF Maintenance: Concept and Importance in Pharmacovigilance.